Autologous cell suspension grafting using ReCell in vitiligo and piebaldism patients: a randomized controlled pilot study - Autologous cell suspension grafting using ReCell

Stichting Nederlands Instituut voor Pigmentstoornissen0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年4月29日

试验速览

暂无简介。

•Patients with segmental vitiligo or piebaldism under medical treatment at the Netherlands Institute for Pigment Disorders
•Patient is willing and able to give written informed consent
•Segmental vitiligo stable since 12 months without systemic therapy or 6 months without topical therapy as defined by the absence of new lesions and/or enlargement of existing lesions.
•At least three vitiligo lesions on the proximal extremities or trunk larger than 3x3 cm or one vitiligo

•UV therapy or systemic immunosuppressive treatment during the last 12 months
•Local treatment of vitiligo during the last 12 months
•Vitiligo lesions with folliculair or non-folliculair repigmentations
•Skin type I and II
•Recurrent HSV skin infections
•Hypertrophic scars
•Cardial insufficiency
•Patients with a history of hypersensitivity to (UVB or UVA) light and/or allergy to local anesthesia.
•Patients who are pregnant or breast-feeding
•Patients not competent to understand what the procedures involved
•Patients with a personal history of melanoma or non-melanoma skin cancer
•Patients with a first degree relative with melanoma skin cancer
•Patients with atypical nevi.

发起方

Stichting Nederlands Instituut voor Pigmentstoornissen